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A B S T R A C T
A new cycloartane sapogenol and a new cycloartane xyloside were isolated from Astragalus karjaginii BORISS
along with thirteen known compounds. The structures of the new compounds were established as 3-oxo-
6α,16β,24(S),25-tetrahydroxycycloartane (1) and 6-O-β-D-xylopyranosyl-3β,6α,16β,24(S),25-pentahydrox-
ycycloartane (2) by 1D- and 2D-NMR experiments as well as ESIMS and HRMS analyses. The presence of the keto
function at position 3 was reported for the first time for cyclocanthogenol sapogenin of Astragalus genus. In vitro
immunomodulatory effects of the new compounds (1 and 2) along with the n-BuOH and MeOH extracts of A.
karjaginii at two different doses (3 and 6 μg) were tested on human whole blood for in vitro cytokine release (IL-2,
IL-17A and IFN-γ) and hemolytic activities. The results confirmed that compound 2, a monodesmosidic saponin,
had the strongest effect on the induction of both IL-2 (6 μg, 6345.41 ± 0.12 pg/mL (×5), P < 0.001) and a
slight effect upon IL-17A (3 μg, 5217.85 ± 0.72 pg/mL, P < 0.05) cytokines compared to the other test
compounds and positive controls (AST VII: Astragaloside VII; and QS-21: Quillaja saponin 21). All tested extracts
and molecules also induced release of IFN-γ remarkably ranging between 5031.95 ± 0.05 pg/mL, P < 0.001
for MeOH extract (6 μg) and 5877.08 ± 0.06 pg/mL, P < 0.001 for compound 1 (6 μg) compared to QS-21
(6 μg, 5924.87 ± 0.1 pg/mL, P < 0.001). Administration of AST VII and other test compounds did not cause
any hemolytic activity, whereas QS-21 resulted a noteworthy hemolysis.
1. Introduction
Astragalus L., which is the largest genus in the family Leguminosae,
is represented by 850 species, 527 of which are endemic, in the flora of
Iran [1,2]. The isolation of a series of cycloartane and oleanane tri-
terpenoids was reported from Astragalus species [3–13]. Their tradi-
tional and modern usages are primarily for immune-related complaints
(frequent infections) or malignancies [14]. The crude Astragalus pre-
parations are used for treating some illnesses such as leukemia, re-
spiratory infections and diabetes in Iranian folk medicine [15].
Astragalus is generally considered as safe with few reported adverse
events. Its extracts have been shown to enhance NK cells' activity
leading to efficient elimination of tumor cells, together with stimulating
the activity of other immune cells such as macrophages and B-cells
[16–18]. A purified mixture containing mostly saponins (PMS) from
Astragalus corniculatus against myeloid Graffi tumor in hamsters showed
that the mixture could decrease the tumor transplantability, inhibit
tumor growth in the early stages of tumor progression, reduce the
percentage mortality and finally increase the mean survival time [19].
Kim and co-workers reported that the extract of Astragalus membrana-
ceus suppressed the expression of Th2 cytokines and significantly de-
creased the TNF-α level. They also confirmed that the extract was ef-
fective for treatment of atopic dermatitis via regulating cytokines [20].
Among Astragalus constituents, mainly polysaccharides and cy-
cloartane-type saponins were shown to be effective; the latter were
more prominent to exhibit insecticidal, antifungal, cytotoxic, anthel-
mintic, immunostimulant and anti-inflammatory activities [1,21–24].
AST VII, a tridesmosidic glycoside from Astragalus species, was
found to be the most active cycloartane during our screening studies to
induce IL-2 production (%139.6) [25]. Astragaloside I was the only
effective compound on increasing not only NF-κB-directed luciferase
expression up to 65% but also the mRNA expression of inflammatory
cytokines, such as IL-1β and TNF-α [14]. When adjuvant and hemolytic
effects of IL-2 stimulating Astragalus saponins, namely AST VII and
MacB (Macrophyllosaponin B) were evaluated in vitro and in vivo, the
test compounds exhibited remarkable adjuvanicity with safe profiles
http://dx.doi.org/10.1016/j.fitote.2017.08.008
Received 29 June 2017; Received in revised form 16 August 2017; Accepted 17 August 2017
⁎ Corresponding author.
E-mail address: erdalbedir@iyte.edu.tr (E. Bedir).
Fitoterapia 122 (2017) 26–33
Available online 18 August 2017
0367-326X/ © 2017 Elsevier B.V. All rights reserved.
MARK
warranting further studies to be tested in vaccine formulations [26].
In the present paper, as a continuation of our search on Astragalus
genus to establish new bioactive compounds with immunostimulatory
properties, A. karjaginii was studied that resulted in the isolation of two
new cycloartane-type triterpenoids (1–2) along with thirteen known
ones (3–15). The structure elucidation was completed by spectroscopic
methods including 1D- (1H, 13C), 2D-NMR (DQF-COSY, HSQC, and
HMBC) and HRMS analyses. Additionally, the methanol and n-butanol
extracts together with the new compounds (1 and 2) were tested for in
vitro cytokine release (IL-2, IL-17A and IFN-γ) in activated whole blood
cells by PMA plus ionomycin, as well as for their hemolytic activities in
human erythrocyte cells.
2. Results
The molecular formula of 1 was determined as C30H50O5 by
HRESIMS data (m/z 513.3563 [M+ Na]+, calcd 513.3560 for
C30H50O5Na), implying an unsaturation degree of 6. The 1H NMR
spectrum of 1 showed resonances due to a cyclopropane methylene at δ
0.63 and 0.43 (each 1H, d, J= 4.0 Hz), six tertiary methyl groups at δ
1.33 (3H, s), 1.20 (6H, s), 1.15 (3H, s), 1.14 (3H, s) and 0.92 (3H, s),
and a secondary methyl group at δ 0.90 (d, J= 6.0 Hz), suggesting a
cycloartane-type triterpene nucleus (Fig. 1, Table 1). Additionally,
three low-field proton resonances at δ 4.48 (ddd, J= 8.0, 8.0, 5.0 Hz),
3.56 (dd, J= 10.5, 2.5 Hz), and 3.51 (ddd, J= 9.0, 9.0, 4.5 Hz) were
observed, and their secondary alcoholic characters were confirmed by
HSQC correlations.
In the low-field of 13C NMR spectrum, in addition to oxymethine
resonances, a tertiary alcohol carbon at δ 73.4 and a carbonyl carbon at
δ 217.4 were also noticed (Table 2). The presence of a double bond as
ketone group suggested that the skeleton had pentacyclic nature in-
cluding the characteristic cyclopropane ring.
A detailed analysis of 1H and 13C NMR data, and comparison with
those of cycloartane-type aglycones derived from Astragalus genus
proposed that compound 1 was closely related with cyclocanthogenin
[3β,6α,16β,24(S)-25-pentahydroxycycloartane] [27] (Tables 1 and 2).
Complete NMR assignments of 1 were accomplished by HSQC and
COSY experiments, whereas to reveal the complete skeleton via con-
necting the partial structures, the HMBC spectrum was evaluated
(Fig. 2).
It was evident from 1H NMR spectrum that the oxymethine proton
He3 of cyclocanthogenin (δ 3.20) was absent in compound 1, whereas,
in the 13C NMR spectrum, secondary alcohol of cyclocanthogenin's Ce3
(δ 79.6) was replaced with a ketone resonance (δ 217.4), inferring
compound 1′s structure as cyclocanthogenin-3-one. The HMBC corre-
lations between the proton resonances at δ 1.33 and 1.20 assigned for
Me-28 and Me-29, respectively, with the carbon resonance at δ 217.4
Fig. 1. Structures of compounds 1, 2 and 2a.
Table 1
1H NMR data (J in Hz) of compounds 1, 2 and 2a (500Mz, δ ppm, in CDCl3, CD3OD and
CDCl3, respectively).
H 1
δH (J in Hz)
2
δH (J in Hz)
2a
δH (J in Hz)
1 2.06, 1.36, m 1.56, 1.28, m 1.21, 1.60, m
2 2.61, 2.42, m 1.91, 1.87, m 1.78, 1.55, m
3 – 3.20, dd (11.2, 4.0) 4.50, dd (11.0, 4.5)
4 – – –
5 1.92, d (9.0) 1.58, d (9.5) 1.63, d (9.2)
6 3.51, ddd (9.0,
9.0, 4.5)
3.52, ddd (9.5, 9.5,
4.5)
3.38, td (8.8, 3.8)
7 1.40, m 1.77, 1.62, m 1.48, 1.70, m
8 1.76, dd (12.0,
4.0)
1.87, dd (12.0, 4.2) 1.75, dd (10.8, 4.7)
9 – – –
10 – – –
11 1.56, 1.40, m 1.84, 1.42, m 1.84, 1.42, m
12 1.65, m 1.62, m 1.61, m
13 – – –
14 – – –
15 2.02, dd (12.0,
8.0)
2.05, dd (12.7, 8.0) 1.22, m
1.35, dd (12.0,
5.0)
1.37, dd (12.7, 5.2) 2.17, dd (13.7, 8.3)
16 4.48, ddd (8.0,
8.0, 5.0)
4.43, ddd (8.0, 8.0,
5.2)
5.25, ddd (6.1, 7.5, 7.5)
17 1.63, dd (9.5,
8.2)
1.69, dd (9.9, 8.0) 1.85, m
18 1.15, s 1.14, s 1.10, s
19 0.63, d (4.0) 0.56, d (4.2) 0.30, d (4.5), 0.49, d (4.4)
0.43, d (4.0) 0.23, d (4.2)
20 1.91, m 1.90, m 1.83, m
21 0.90, d (6.0) 0.94, d (6.5) 0.91, d (5.8)
22 1.84, 1.07, m 1.80, 1.24, m 1.01, 1.28, m
23 2.04, 1.03, m 1.65, 1.45, m 1.52, 1.60, m
24 3.56, dd (10.5,
2.5)
3.38, dd (10.5, 2.4) 4.68, dd (9.6, 2.2)
25 – – –
26 1.20, s 1.15, s 1.18, s
27 1.14, s 1.16, s 1.18, s
28 1.33, s 1.18, s 0.91, s
29 1.20, s 0.92, s 0.97, s
30 0.92, s 0.98, s 0.93, s
1′ 4.29, d (7.5) 4.57, d (6.6)
2′ 3.17, dd (7.5, 9.0) 4.87, dd (8.5, 6.7)
3′ 3.28, t (9.0) 5.11, t (8.5)
4′ 3.45, m 4.93, td (8.3, 5.2)
5′ 3.82, dd (5.2, 11.4),
3.16, t (11.4)
4.10, dd (11.9, 5.0), 3.32,
dd (11.9, 8.4)
COCH3 1.99 (×2), 2.01, 2.03,
2.04, 2.10
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allowed us to facilitate the keto group at Ce3 (Fig. 2). Additionally, the
relative configurations of the oxygenated atoms were determined by the
magnitude of the vicinal proton-proton coupling constants to be αeOH
for Ce6 (δ 3.51, ddd, J= 9.0, 9.0, 4.5 Hz, Haxe6) and βeOH for Ce16
(δ 4.48, ddd, J= 8.0, 8.0, 5.0 Hz, Haxe16). 1H and 13C NMR data for
He24 and Ce24 are comparable to those reported for analogous
compounds having a 24S configuration [9,11,12]. Thus, the structure of
1 was elucidated as 6α,16β,24(S),25-tetrahydroxycycloartane-3-one.
The HRESIMS spectrum of 2 (m/z 647.4147 [M + Na]+, calcd for
C35H60O9Na, 647.4145) supported a molecular formula of C35H60O9Na.
The 1H NMR spectrum of 2 showed resonances due to a cyclopropane
methylene at δ 0.56 and 0.23 (each 1H, d, J= 4.2 Hz), six tertiary
methyl groups at δ 1.18 (3H, s), 1.16 (3H, s), 1.15 (3H, s), 1.14 (3H, s),
0.98 (3H, s) and 0.92 (3H, s), a secondary methyl group at δ 0.94 (d,
J= 6.5 Hz), and four methine proton resonances at δ 4.43 (ddd,
J= 8.0, 8.0, 5.2 Hz), 3.52 (ddd, J= 9.5, 9.5, 4.5 Hz), 3.38 (dd,
J= 10.5, 2.4 Hz) and 3.20 (dd, J= 11.2, 4.0 Hz), which were in-
dicative of secondary alcoholic functions (Fig. 1, Table 1). On the other
hand, the relative configurations of the oxygenated atoms were de-
termined by the magnitude of the vicinal proton-proton coupling con-
stants to be: Ce3 (βeOH; δ 3.20, dd, J= 11.2, 4.0 Hz. Haxe3), Ce6
(αeOH; δ 3.52, ddd, J= 9.5, 9.5, 4.5 Hz, Haxe6) and Ce16 (βeOH; δ
4.43, ddd, J= 8.0, 8.0, 5.2 Hz, Haxe16). 1H and 13C NMR data for
He24 and Ce24 are comparable to those reported for analogous
compounds having a 24S configuration [9,11,12]. The NMR data of the
aglycone moiety of 2 were in good agreement with those reported for
cyclocanthogenin [3] with glycosylation shift for Ce6 (δ 79.6)
(Table 2). The 1H NMR spectrum of 2 displayed only one anomeric
proton resonance at δ 4.29 (d, J= 7.5 Hz) in the sugar region verifying
a monosaccharidic sapogenol. Full assignments of the proton and
carbon resonances of 2 were secured by COSY and HMQC spectra. On
the basis of proton and carbon data and comparison with those of
previously identified cyclortane glycosides from Astragalus genus, the
sugar unit was readily identified as β-xylopyranosyl unit.
As explained in the experimental part, compound 2 was first iso-
lated in its acetylated form due to separation difficulties. Acetylated
form of 2 yielded a hexaacetate, 2a. The IR spectrum of 2a still ex-
hibited a free OH absorption band after acetylation (3450 cm−1), in-
dicating the presence of a free hydroxyl group on 2. The acetylation
pattern of the sugar residue (Ce2xyl, Ce3xyl and Ce4xyl) was readily
deduced from the COSY spectrum of 2a, which showed significant
downfield shifts for He2xyl, He3xyl and He4xyl resonances ranging
between 1.5 and 1.9 ppm (see Table 1). The remaining 3 acetoxyl re-
sonances deriving from the sapogenol moiety also implied a non-
acetylated OH group. Indeed, the resonances due to He3, He16 and
He24 were observed at δ 4.50, 5.25 and 4.68, respectively, exhibiting
the expected downfield shift in comparison to 2 (δ 3.20, 4.43 and 3.38,
respectively). No downfield shifts were observed for H-6, supporting
the site of glycosidation. These results clarified the site of the non-
acetylated hydroxyl group on the sapogenol moiety as Ce25 with ter-
tiary alcohol character. Full NMR assignments of 2a were also secured
by COSY and HSQC. In order to establish the interfragment relation-
ship, HMBC was performed, which not only connected the fragments
but also proved xylose residue's position (Fig. 2). Thus, the 3JCeH long-
distance correlation between the proton resonance at δ 4.57 (He1xyl)
and the carbon resonance at δ 79.1 (Ce6) allowed us to determine the
linkage site.
The acid hydrolysis of 2 afforded D-xylose (confirmed by the optical
rotation data of isolated sugar). Thus, compound 2 was elucidated as 6-
O-β-D-xylopyranosyl-3β,6α,16β,24(S),25-pentahydroxycycloartane.
Table 2
13C NMR data of compounds 1, 2 and 2aa (125 MHz, δ ppm, in CDCl3, CD3OD and CDCl3,
respectively).
C 1
δC
2
δC
2a
δC
1 31.9 33.4 31.4
2 35.8 29.9 26.6
3 217.4 79.6 80.2
4 50.4 42.7 40.2
5 53.8 52.8 51.5
6 69.9 79.6 79.1
7 37.8 34.0 33.9
8 48.1 46.3 45.8
9 21.5 22.0 21.0
10 28.2 29.0 28.6
11 26.3 26.6 26.0
12 32.6 34.0 32.3
13 45.5 46.2 46.9
14 46.6 46.6 45.4
15 47.9 47.9 45.4
16 72.8 73.4 75.6
17 57.1 58.0 54.1
18 19.3 18.1 19.9
19 31.2 28.4 29.1
20 26.6 29.0 30.4
21 17.8 18.4 18.2
22 31.4 33.8 32.5
23 26.1 28.6 26.6
24 75.4 78.4 80.5
25 73.4 74.0 72.6
26 27.2 25.3 25.3
27 23.2 25.4 26.8
28 28.4 28.4 27.7
29 20.3 15.8 16.7
30 20.4 19.8 19.7
1′ 105.4 101.1
2′ 75.5 71.5
3′ 78.1 71.9
4′ 71.3 79.1
5′ 66.6 62.1
a COCH3: 20.88 (×2), 21.14, 21.14, 21.39, 21.44; COCH3: 169.5, 169.9, 170.4, 171.0,
171.4, 172.4.
Fig. 2. Key long-range correlations [HMBCs (H to C)] of 1 and 2a.
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Additionally, cycloastragenol (3) [4], cyclocanthoside E (4) [28],
astragaloside IV (5) [29], astragaloside VIII (6) [30], cycloascauloside B
(7) [31], cyclocephaloside I (8) [3], astrachrysoside A (9) [32], 3-O-[α-
L-rhamnopyranosyl-(1→ 2)-α-L-arabinopyranosyl-(1→ 2)-β-D-xylo-
pyranosyl]-6-O-β-D-glucopyranosyl-3β,6α,16β,24(S),25-pentahydrox-
ycycloartane (10) [9], 3-O-[α-L-rhamnopyranosyl-(1→ 2)-α-L-arabi-
nopyranosyl-(1→ 2)-β-D-xylopyranosyl]-6-O-β-D-glucopyranosyl-
3β,6α,16β,24α-tetrahydroxy-20(R), 25-epoxycycloartane (11) [9], 3-O-
[α-L-arabinopyranosyl-(1→ 2)-β-D-xylopyranosyl]-6-O-β-D-glucopyr-
anosyl-3β,6α,16β,24α-tetrahydroxy-20(R),25-epoxycycloartane (12)
[9], cyclocephalosoide I (13) [16], 6-O-β-D-glucopyranosyl-
3β,6α,16β,24α-tetrahydroxy-20(R),25-epoxycycloartane (14) [33] and
cyclocanthoside A (15) [34] were also isolated from Astragalus karja-
ginii, and identified based on comparison of their spectroscopic data
with literature values.
In this study, the analyses of IL-2, IFN-γ and IL-17A cytokine release
in stimulated whole blood using PMA plus ionomycin were determined
by ELISA. Two compounds, viz. QS-21 and AST VII, were used as po-
sitive controls.
Compared to whole blood control group induced by PMA plus io-
nomicin (6273.41 ± 0.21 pg/mL, ×5), the results showed that the
compounds (1 and 2) besides the n-BuOH and MeOH extracts enhanced
the secretion of IL-2 considerably in both test doses (3 and 6 μg)
(Fig. 3). It is obvious that the presence of sugar unit results a slight
variation for IL-2 secretion. For instance, for both 3 and 6 μg doses,
monosaccharidic 2 (7266.16 ± 0.17 0.09 pg/mL, (×5), P < 0.001
and 6985.18 ± 0.04 pg/mL, (×5), P < 0.001) was more effective
than compound 1 for IL-2 release [(6261.71 ± 0.09 pg/mL, (×5),
P < 0.001 and 6345.41 ± 0.12 pg/mL, (×5), P < 0.001), respec-
tively]. On the other hand, the positive controls QS-21 (6 μg,
7219.51 ± 0.09 pg/mL, (×5), P < 0.001) and AST VII (6 μg,
6560.84 ± 0.29 pg/mL, (×5), P < 0.001) were also active but not as
much as compound 2′s lower dose of 3 μg.
In the case of IL-17A secretion, except compound 2 (3 μg,
5217.85 ± 0.72 pg/mL, P < 0.05) which showed slight induction
upon IL-17A cytokine comparing to PMA + Iyonomycin
(4883.42 ± 0.072, (×5), pg/mL), none of the compounds showed any
effect.
QS-21 was found to be the most active compound towards induction
of IFN-γ release (6 μg, 5924.87 ± 0.1 pg/mL, P < 0.001), whereas all
the test compounds and extracts had also notable effects. Among them,
compound 1 showed the most prominent effect on IFN-γ production at
6 μg (5877.08 ± 0.06 pg/mL, P < 0.001) compared to whole blood
control group induced by PMA plus ionomicin (4883.42 ± 0.071 pg/
mL, P > 0.05).
A. karjaginii extracts and the new compounds were also investigated
for their hemolytic activities. As it is shown in Table 3, QS-21 caused
strong hemolysis at all test concentrations (500, 250, 125, 50 μg/mL,
P < 0.001), whereas the Astragalus compounds (1, 2 and AST VII) and
extracts exhibited no hemolytic effect.
3. Discussion
Cytokines with peptide-based structures have crucial roles in the
human immune system, such as inflammatory response, autoimmunity,
Fig. 3. Immunomodulatory activities of the n-butanol
and methanol extracts of A. karjaginii, and compounds
1 and 2.
Table 3
Hemolytic activities of n-butanolic, methanolic extracts, and compounds 1 and 2.a,b,c
Group (μg/mL) Absorbance value Hemolytic percentage (%)
Saline 0.140 ± 0.004 0.00 ± 0.60
Distillated water 1.024 ± 0.04 100.00 ± 5.88***
QS-21500 1.112 ± 0.044 87.19 ± 5.52***
QS-21250 0.767 ± 0.008 60.04 ± 1.07***
QS-21125 0.710 ± 0.009 55.26 ± 1.17***
QS-21 50 0662 ± 0.0002 50.25 ± 1.11***
AST VII 500 0.145 ± 0.001 −1.51 ± 0.33
AST VII 250 0.112 ± 0.003 −2.08 ± 0.16
AST VII 125 0.103 ± 0.003 −2.39 ± 0.14
AST VII 50 0.100 ± 0.006 −4.47 ± 0.54
Compound 1500 0.131 ± 0.005 −2.91 ± 0.69
Compound 1250 0.119 ± 0.001 −4.09 ± 0.15
Compound 1125 0.097 ± 0.002 −6.40 ± 0.26
Compound 1 50 0.078 ± 0.001 −8.33 ± 0.17
Compound 2500 0.157 ± 0.001 −0.30 ± 0.20
Compound 2250 0.141 ± 0.001 −1.89 ± 0.15
Compound 2125 0.096 ± 0.002 −6.46 ± 0.25
Compound 2 50 0.082 ± 0.001 −8.05 ± 0.20
Butanol extract 500 0.188 ± 0.002 2.87 ± 0.31
Butanol extract 250 0.146 ± 0.002 −1.35 ± 0.32
Butanol extract 125 0.097 ± 0.001 −6.33 ± 0.15
Butanol extract 50 0.188 ± 0.002 −7.24 ± 0.25
MeOH extract 500 0.185 ± 0.002 2.60 ± 0.29
MeOH extract 250 0.142 ± 0.002 −1.76 ± 0.25
MeOH extract 125 0.094 ± 0.008 −6.70 ± 0.10
MeOH extract 50 0.085 ± 0.008 −7.617 ± 0.10
a *p < 0.05; **p < 0.01; ***p < 0.001.
b Hemolytic percents of saline and distilled water were included as minimal and
maximal hemolytic control.
c All values represent the mean ± standard deviation (n 1/4 3 test).
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normal T-cell-mediated immunity, cancer and allergy [35–38]. The
immune response is categorized in two groups based on the cytokine
profile induced: Th1 or Th2. The Th1 profile is described by the initial
production of IFN-γ and IL-12 with an effector phase of T lymphocytes
producing IL-2 and IFN-γ and mediating cytotoxic activity (CTL). In
contrast, Th2 responses are put forth by IL-4 with predominantly IL-5
and IL-10 producing T cells in the active phase driving antibody pro-
duction [19,21,23,39–41]. IL-17A is the principal member of the family
named IL-17A cytokine group [42]. The essential roles of this family are
induction and facilitation of pro-inflammatory responses [43]. IL-17A
inhibitors are under investigation to treat autoimmune diseases like
rheumatoid arthritis, psoriasis and inflammatory bowel disease. The
role of IL-17A for Th17 cells in vitiligo pathogenesis was also confirmed
[44]. Concisely, IL-2, IFN-γ and IL-17A are major cytokines with dif-
ferent functions for the immune system, and developing new molecules
modulating them will have a potential use in therapy. Additionally,
based on the earlier studies, one might advise that the specific mole-
cules turning on the cytokine gene expression is more beneficial than
injectable cytokines possessing too low therapeutic index [45–48].
Astragalus preparations have been shown to stimulate immune
system on cellular and humoral level. Earlier studies undeniably
pointed to induction of cytokines such as interleukins and interferons
for their immunostimulatory actions [26,49,50]. The purified compo-
nents of crude Astragalus preparations such as polysaccharides and sa-
ponins were found to be major contributors of the immunomodulatory
actions [14,50,51]. Thus, Astragalus species and their constituents de-
serve detailed investigation for their immunomodulatory properties.
In one of our previous reports, Astragalus extracts and their cy-
cloartane-type saponins were screened for their immunomodulatory
properties via measuring cytokine levels (IL-1β, IL-8 and TNF-α, IL-2,
IL-4 and IFN-γ), which revealed noteworthy effects on IL-2 induction
[25]. In the same study, the crude saponin extract of Astragalus oleifo-
lius, rich in acyclic side-chain bidesmosidic saponins, was found to be
the most active fraction with 141.2% IL-2 induction at 3 μg/mL. In
contrast, purified glycosides of 20,24-epoxy and 20,25-epoxy side-chain
cycloartanes showed higher IL-2 inducing activity than those of acyclic-
cycloartane derivatives as well as the aglycone of 20,24-epoxy cy-
cloartanes, cycloastragenol. In a continuation of this study, one of the
major components of A. oleifolius, namely Mac B, were shown to be a
potent adjuvant in vivo via increasing BSA-specific IgG, IgG1 and IgG2b
antibody titers, and IFN-γ level at 90 μg dose, inferring potential of
acyclic side-chain cyloartane glycosides.
Compared to the results of Yesilada et al. and Nalbantsoy et al., this
study made the structure-activity relationship more complicated for
cycloartane chemistry [25,26]. Firstly, the monoglycosidic compound 2
with acyclic side chain exhibited stronger or equal potency on IL-2 and
IFN-γ induction compared to the positive controls, QS-21 and tri-
desmosidic AST VII. This suggested that the number of sugar units ex-
tending from aglycone is not as significant as it thought to be for cy-
cloartane chemistry. Secondly, the Ce3 oxidized form of
cyclocanthogenol (1), sapogenin of compound 2, also provided sig-
nificant effects on the release of the same cytokines. Based on this data,
one might hypothesize that the sapogenin framework with acyclic side-
chain is more important than the sugar content on the structure. These
findings contradict the results of earlier studies dealing with saponin
structure-immunostimulatory activity relationships, which mostly em-
phasized the presence of long-chain branched/unbranched sugar units
extending from Ce3 and Ce28 positons, acylation on the saccharidic
parts, and an aldehyde function on the aglycone for higher activity
[52–54].
On the other hand, except compound 2 at the dose of 3 μg with a
slight effect, none of the tested compounds showed notable effect on IL-
17A secretion. As IL-17A is a key pro-inflammatory cytokine, the pa-
tients with autoimmune diseases must approach to formulations of
Astragalus precariously.
Saponins are well-known for their hemolytic effects. The overriding
basis of hemolysis has been determined to be cell membrane swelling
due to pore formation, partial entry of extracellular Ca2+ and ceramide
formation [55–57]. In this study, the extracts of A. karjaginii and the
new compounds were also evaluated for their hemolytic activities,
which showed no hemolysis on erythrocytes. On the other hand, the
only saponin-type adjuvant QS-21, which is in clinical trials as part of
human vaccine formulations, displayed high hemolytic activity,
whereas the other positive control AST VII caused no hemolysis.
Based on the safer profile mentioned above, we believe that the
cycloartane-saponins of Astragalus species are good candidates for
vaccine formulations requiring higher immune response. Consequently,
our findings warrant further studies focusing on the in vivo potential of
the tested saponins and their mechanism of actions.
4. Materials and methods
4.1. Experimental
Optical rotations were measured on a standard Bruker program on
an Ultra Shield Plus 500 MHz (Bruker) (NMR Unit at the College of
Pharmacy, Prince Sattam Bin Abdulaziz University) spectrometer op-
erating at 500 MHz for proton and 125 MHz for carbon. The chemical
shift values were represented in δ (ppm) comparing to the residual
solvent peak, and the coupling constants (J) were reported in Hertz
(Hz) and MS spectra were measured on a LC/MS High resolution Time
of Flight (TOF) Agilent 1200/6530 instrument; CC, silica gel 60
(MERCK); GPC (General Permeation Chromatography, Sephadex LH-
20). All 2D NMR spectra were obtained in CDCl3 and CD3OD (99.50%,
Sigma Aldrich) standard pulse sequences and phase cycling were used
for COSY, HSQC and HMBC spectra.
4.2. Plant material
The root and stem of A. karjaginii were collected from Naghadeh
City, Sheykhan Mountain, altitude of 2450 m, West Azerbaijan
Province, Iran, in August 2013, and identified by Dr. Ali-Asghar
Massoumi (botanist) in Research Institute of Forests and Rangelands. A
voucher has been deposited (Tehran 19,537) at the Herbarium of
Research and Application Center in Research Institute of Forests and
Rangelands, Tehran, Iran.
4.3. Extraction and isolation
The root of the plant material (1000 g) was extracted with MeOH
(5 × 6 L) for 5 days under reflux. After filtration, the solvent was re-
moved by rotary evaporation to obtain a dark residue (101.0 g). Then it
was suspended in water (800 mL), and respectively was partitioned
with n-hexane (4 × 400 mL), CH2Cl2 (4 × 400 mL), EtOAc
(4 × 400 mL) and neBuOH (4 × 400 mL). The BuOH extract (70 g)
was subjected to VLC (Lichroprep RP-18, 25–40 μm, 180 g) using re-
versed-phase silica gel utilizing MeOHeH2O solvent systems employing
H2O (1000 mL), H2O–MeOH (80:20, 1200 mL; 60:40, 2400 mL; 40:60,
3200 mL; 20:80, 1800 mL) and MeOH (800 mL) to give 20 main frac-
tions (A to T). Fraction C was applied to an open column chromato-
graphy using normal-phase silica gel (23 × 1200 mm, 600 g) as sta-
tionary phase with the solvent system CHCl3eMeOHeH2O (90:10:1,
2000 mL; 80:20:2, 1500 mL; 70:30:3, 2000 mL) resulting to fractions
C1eC986. The fractions C600 to C712 (1.0 g) were combined and ap-
plied to vacuum liquid chromatography (VLC) using reversed-phase
silica gel (Lichroprep RP-18, 25–40 μm) employing MeOHeH2O solvent
system (40:60, 700 mL; 50:50, 1500 mL; 60:40, 1500 mL; 70:30,
1000 mL; 80:20, 1000 mL and MeOH, 700 mL) to yield 1 (15 mg) and 3
(400 mg). Fraction K (6.0 g) was also applied to an open column
chromatography containing normal-phase silica gel (30 × 1200 mm,
600 g) with the solvent system (90:10:1, 2000 mL; 85:15:1.5, 2300 mL;
80:20:2, 1000 mL; 75:25:2.5, 1000 mL; 70:30:3, 800 mL; 61:32:7,
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1500 mL; 64:50:10, 2000 mL) to provide 3119 subfractions.
Subfractions 600 and 894 (56 mg) were combined and applied over
reversed-phase material (Lichroprep RP-18, 25–40 μ, 35 g) eluting with
MeOHeH2O (50:50, 800 mL; 60:40, 500 mL; 70:30, 500 mL; 80:20,
900 mL; 90:10, 600 mL; 100:0, 800 mL) yielding 4 (9.0 mg) and 5
(14 mg). K900 and K1168 (250 mg) were combined and eluted with
CHCl3-MeOH-H2O (85:15:1.5, 600 mL; 80:20:2, 500 mL; 75:25:2.5,
1000 mL; 70:30:3, 600 mL) over an open column chromatography in-
cluding normal-phase silica gel (22 × 900 mm, 200 g) to give sub-
fractions KA1-KA589, from which subfractions KA200-KA332 (54 mg)
were combined and subjected to open column chromatography filled
with reversed-phase material (Lichroprep RP-18, 25–40 μm, 38 g)
eluting with MeOH-H2O (50:50, 300 mL; 60:40, 300 mL; 70:30,
300 mL; 80:20, 250 mL; 90:10, 100 mL; 100:0, 100 mL) to give com-
pound 6 (10 mg) and 7 (38 mg). Fractions K1456-K1561 were com-
bined and further separated over normal phase silica gel
(20 × 250 mm, 60.6 g) using a step-gradient of EtOAc-MeOH-H2O
(100:10:5, 300 mL; 100:15:7.5, 400 mL; 100:17.5:13.5, 350 mL;
100:20:15, 200 mL; 100:25:20, 300 mL) to give 489 subfractions (KB1-
KB489). Subfractions KB161-KB178 (35 mg) were combined and
chromatographed over normal phase silica gel (22 × 390 mm, 90 g)
employing with CHCl3-MeOH-H2O (90:10:1, 200 mL; 80:20:1, 400 mL;
80:20:2, 150 mL; 70:30:3, 200 mL; 61:32:7, 100 mL) mixtures and
methanol to afford compounds 8 (10 mg) and 9 (9.3 mg). Subfractions
KB200-KB310 (55 mg) were combined and subjected to column chro-
matography containing reversed-phase material (Lichroprep RP-18,
25–40 μm, 88 g) and eluted with isocratic MeOHeH2O mobile phase
system (60:40, 300 mL; 40:60, 500 mL; 20:80, 700 mL) to give a mix-
ture including two compounds (45 mg). As the open column chroma-
tography silica gel and RP-18 trials failed to separate these two meta-
bolites from the mixture due to their similar polarities, the mixture was
acetylated using acetic anhydride and pyridine. After acetylation, the
mixture was applied to column chromatography by using normal-phase
silica gel (20 × 260 mm, 22.2 g) eluting with CHCl3-acetone (80:20,
300 mL; 70:30, 300 mL; 60:40, 200 mL; 50:50, 200 mL; 40:60, 100 mL)
to yield compound 2a (25 mg). Then, compound 2a (5 mg) was dea-
cetylated to obtain compound 2 (2.5 mg). Before the acetylation reac-
tion took place, the mixture was analyzed by 1H NMR to make sure that
no acetyl group was present in the structure of the starting compounds.
Fractions O2687-O2900 (4.0 g) were mixed and subjected to an open
column chromatography using silica gel (30 × 1200 mm, 500 g) as
stationary phase using (90:10:1, 1500 mL; 80:20:2, 2500 mL; 70:30:3,
1000 mL) concluding 1432 subfractions. Subfractions O200-O453
(226 mg) were combined and fractionated over reversed-phase material
(Lichroprep RP-18, 25–40 μm, 106 g) using reversed-phase silica pro-
cessing with MeOH-H2O (50:50, 1000 mL; 40:60, 3000 mL; 30:70,
1000 mL; 20:80, 2000 mL and MeOH, 800 mL) mixture to afford com-
pounds 12 (9.4 mg) and 13 (11 mg). Subfractions O600-O836 (400 mg)
were combined and separated over normal phase silica gel
(23 × 450 mm, 60.6 g) using a step-gradient of EtOAc-MeOH-H2O
(100:10:5, 400 mL; 100:15:7.5, 450 mL; 100:17.5:13.5, 500 mL;
100:20:15, 200 mL; 100:25:20, 250 mL) to give 689 subfractions (OA1-
QA689). After mixing subfractions OA432-OA561 (450 mg), the mix-
ture was separated utilizing CHCl3-MeOH-H2O (80:20:2, 1000 mL;
70:30:3, 900 mL; 61:32:7, 700 mL) over an open column chromato-
graphy filled with normal-phase silica gel (23 × 360 mm, 200 g) to
obtain compound 11 (18 mg) and 10 (10 mg). Subfractions O1002-
O1231 (700 mg) were combined and subjected to an open column
chromatography using CHCl3-MeOH-H2O (95:5:0.5, 900 mL; 90:10:1,
500 mL; 85:15:1.5, 800 mL; 70:30:3, 1200 mL) to acquire 781 fractions
(OB1-OB781), from which fractions OB456-OB741 (200 mg) were
combined and applied to a column chromatography including reversed-
phase material (Lichroprep RP-18, 25–40 μ, 75 g) using MeOH-H2O
(50:50, 400 mL; 40:60, 800 mL; 30:70, 400 mL; 20:80, 500 mL and
MeOH, 600 mL) to afford compounds 14 (8.5 mg) and 15 (12 mg).
4.4. Acid hydrolysis
Fraction Q (1.0 g), a crude saponin extract of A. karjaginii, was he-
ated at 60 °C with 1:1 0.5 N HCl-dioxane (3 mL) for 2 h. After cooling,
the solution was concentrated in rotary. The solution was partitioned
with EtOAc and the H2O part was separated and neutralized with 0.5 M
NaOH. After obtaining the hydrolyzed mixture, three monosaccharides
were purified utilizing normal-phase silica gel as stationary phase
(60 g) eluting with CHCl3-MeOH-H2O solvent system (95:5:0.5,
80:20:1, 80:20:2; 70:30:3; 61:32:7). After separation, the obtained
sugar was identified by comparison with authentic samples tested with
TLC using CHCl3-MeOH-H2O (60:40:10) system. The optical rotation of
purified sugar was measured to afford D-xylose ([α]20D + 22.0, c 0.1,
H2O).
4.5. In vitro bioactivity assays
4.5.1. Immunomodulatory assay: measurement of the effects on cytokine
production
Heparinized peripheral human whole obtained from healthy vo-
lunteers were stimulated with 50 ng PMA (Sigma, St. Lois, MO, U.S.A.)
plus 400 ng ionomycin (Sigma, St. Lois, MO, U.S.A.) for IL-2, IFN-γ and
IL-17A and incubated in the presence of test samples or reference
compound QS-21 for 48 h. The previously cultured supernatants were
collected and the concentration of the cytokines, which were produced
by macrophages or lymphocytes, was measured utilizing a commer-
cially available enzyme-linked immunosorbent assay (ELISA) (Vienne,
Austria). Manufacturer's recommendations were the source for per-
forming the assays. The average absorbance readings of the samples
were then compared with the concentrations of the standard curve. The
concentration of each cytokine in each sample was calculated. The re-
sults of tested cytokines were given as picograms per milliliter. The
minimum detection limits were 9.1 pg/mL, 0.99 pg/mL, and 0.5 pg/mL
for IL-2, IFN-γ and IL-17A, respectively. Diluted supernatants were used
for all assays and each assay was performed in triplicate.
4.5.2. Peripheral whole-blood cultures
The RPMI-1640 medium suspended human whole blood (containing
20 U/mL heparine) was supplemented with %10 FBS, 100 U/mL peni-
cillin and 100 mg/mL streptomycin in a 1:10 ratio. PMA (50 ng/mL)
plus ionomycin (400 ng/mL) were added to the whole blood for pre-
vious stimulation of immune system cells. DMSO was used as stock
solution to dissolve the samples at concentration of 5 mg/mL. Besides,
DMSO was used as negative control. An amount of 1 mL of the hepar-
inized blood stimulated by PMA (50 ng/mL) plus ionomycin (400 ng/
mL) was transferred into each well of 24-well plate and incubated at
37 °C for 48 in the absence or presence of 3 or 6 μg/mL concentrations
of samples or QS-21 and AST VII as positive controls. The diluted cul-
ture supernatants were then mixed with sample diluent at 1:2 ratio.
Furthermore, they were assayed using the specific ELISA method for IL-
2, IFN-γ and IL-17A [26,58,59]. The protocol was approved by the
Human Ethics Committee of Ege University, and all of the used pro-
cedures conformed to the protocol was approved by the Human Ethics
Committee of Ege University, and all of the used procedures conformed
to the declaration of Helsinki. All of the tested were carried out under
approval of the mentioned organization (approval number 15–11/19).
4.5.3. Hemolytic activity assay
The potential for hemolysis of the molecules was calculated ac-
cording to Nalbantsoy et al. (2011) with some modifications [26]. Red
blood cells were collected with BD Vacutainer TM (NH 143 I. U., Bel-
liver Industrial Estate, Plymouth, UK) from human healthy volunteers.
Blood (7 mL) was washed three times using sterile saline solution
(0.89%, w/v NaCl, pyrogen free). Moreover, it was centrifuged at
2000 ×g for 5 min. The pellet diluted to 0.5% with saline solution was
prepared to obtain the final cell suspension. The cell suspension
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(0.01 mL) was mixed in U button 96-well microplate with 0.05 mL di-
luents containing 2.5, 12.5, 25, 50, 125, 250, 500 and 5000 μg/mL
concentrations of molecules in saline solutions. The blends were in-
cubated for 30 min at 37 °C and then were centrifuged at 800 ×g for
10 min. The free hemoglobin belonging to each supernatant was mea-
sured using spectrophotometry at 412 nm. Minimal and maximal he-
molytic controls were saline solution and distilled water respectively.
For measurement of the final hemolytic percent, the hemolytic percent
which was developed by the saline control was subtracted from all
groups. Each experiment was tested as triplicates at each concentration.
5. Statistical analysis
The obtained data were displayed as mean ± standard deviation
(S.D.) and were examined for their statistical significance of difference
with Student t-test, One-way ANOVA and the post hoc test dunnet and
Tamhane's (depends on both normality and homogeneity of the ab-
sorbance values) utilizing SPSS 16.0. P-values < 0.05, 0.01 and 0.001,
were considered significant statistically.
6α,16β,24(S),25-tetrahydroxycycloartane-3-one (1): Amorphous
white solid; C30H50O5; [α]24D - 1.2 (c 0.1 MeOH); IR νKBrmax cm−1: 3430
(> OH), 2920 (> CH), 1740 (C]O); for 1H and 13C NMR (CDCl3,
500 MHz) data see Tables 1 and 2; HRESIMS m/z 513.3563 [M+ Na]+
(calcd. for C30H50O5Na, 513.3560) (positive mode).
6-O-β-D-xylopyranosyl-3β,6α,16β,24(S),25-pentahydroxycycloartane
(2): Amorphous white solid; C35H60O9; [α]24D + 1.6 (c 0.1 MeOH); IR
νKBrmax cm−1: 3420 (> OH), 2900 (> CH); for 1H and 13C NMR (CD3OD,
500 MHz) data see Tables 1 and 2; HRESIMS m/z 647.4147 [M+ Na]+
(calcd. For C35H60O9Na, 647.4145) (positive mode).
6-O-β-D-xylopyranosyl-3β,6α,16β,24(S),25-pentahydroxycycloartane
hexaaacetate (2a): Amorphous white solid; C35H60O9;[α]23D + 6.0 (c 0.2
MeOH), IR νKBrmax cm−1: 3450 (> OH), 1246 (> CH), 1733 (C]O); for
1H and 13C NMR (CDCl3, 500 MHz) data see Tables 1 and 2.
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